CERC On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
text size: T | T
Back to Snapshot
Company Description

Contact Info

400 East Pratt Street

Suite 606

Baltimore, MD 21202

United States

Phone: 410-522-8707

Fax:

ical trials, and to file an IND for CERC-406, subject to the availability of additional funding. Strategy The key elements of the company’s strategy are to pursue financing arrangements to fund pipeline development; pursue non-dilutive funding of pipeline development; explore strategic alternatives; develop CERC-501 as an adjunctive treatment of MDD; and develop CERC-611 as an adjunctive therapy for seizures in patients with epilepsy. Intellectual Property The company has issued patents covering the compounds and compositions of CERC-501, CERC-301, CERC-611 and CERC-406. CERC-501: The company possess worldwide rights to manufacture, use and sell certain KOR antagonist compounds. The CERC-501 patent portfolio consists of a single patent family with dozens of issued patents and pending patent applications, including patents issued in the U.S., Australia, Canada, China, Europe and Japan. The patents in this family include composition of matter claims, including picture claims to CERC-501 or a pharmaceutically acceptable salt thereof, and/or use claims of varying scope. The expiration date of the two U.S. patents is January 13, 2029, not including any potential patent term extension or market exclusivity period. CERC-301: The company possess worldwide rights to manufacture, use and sell certain NR2B antagonist compounds. The CERC-301 patent portfolio consists of three patent families. The first family consists of patents that have issued in the United States, Australia, Canada, Germany, France, Great Britain, Switzerland and Japan. The patents in the first family include composition of matter and use claims of varying scope, including picture claims to CERC-301 or a pharmaceutically acceptable salt thereof. The expiration date of the U.S. patent in the first family is August 31, 2026, not including any patent term extension or market exclusivity period, which might apply. The second family consists of patents that have issued in the United States, Germany, France and Great Britain. The patents in the second family include composition of matter claims (in U.S. patent only) and use claims that generically cover CERC-301. The expiration date of the U.S. patent is June 3, 2022, not including any potential patent term extension or market exclusivity period. The third family consists of a U.S. provisional patent application, which includes claims to compositions of matter, methods of use, and methods of manufacture. U.S. nonprovisional and international patent applications that claim priority to the provisional application were filed in December 2015. Any patent issuing from the U.S. nonprovisional applications would expire in 2035 at the earliest, not including any potential patent term extension or market exclusivity period. CERC-611: The company possess worldwide rights to manufacture, use and sell LY3130481, now known as CERC-611. The CERC-611 patent portfolio consists of two patent families. The first family includes a U.S. patent and approximately 50 international applications with composition of matter and use claims for CERC-611. The projected expiration date of the U.S. patent, exclusive of any patent term extension, is November 20, 2033. The second family includes U.S. and international applications with composition of matter and use claims of varying scope for additional selective TARP ?-8-dependent AMPA receptor antagonists. If granted, patents in the second family are expected to expire on or after May 21, 2035, depending on possible patent term adjustment and/or extension. CERC-406 and COMTi Platform: The company possess worldwide exclusive rights to manufacture, use and sell COMT inhibitor compounds. The COMT patent portfolio includes three patent families. Each patent family consists of patent applications filed in the United States, Australia, Brazil, Canada, China, Europe, India, Japan, South Korea, Mexico and Russia. Any patents issuing from these patent applications are predicted to expire at the earliest in 2031, not including any potential patent term extension or market exclusivity period. Research and Development For the year ended December 31, 2016, the company’s research and d

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CERC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CERC.
View Industry Companies
 

Industry Analysis

CERC

Industry Average

Valuation CERC Industry Range
Price/Earnings 79.3x
Price/Sales 4.0x
Price/Book 7.9x
Price/Cash Flow 23.0x
TEV/Sales 4.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CERECOR INC, please visit www.cerecor.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.